The useful question with this in-depth comparison is not whether one photo looks better or worse. It is whether the pattern, timing, measurements, and treatment trade-offs point to a decision that will still make sense six months from now.
Last fall a friend of mine, a 31-year-old software developer in Austin named Jordan, texted me a photo of his wet hair after a shower. “Is this normal?” The image showed a scalp where the hair looked thin everywhere, not receding at the temples, not clearing at the crown, just uniformly less. His barber had told him it was “just MPB.” His primary care doctor said it might be stress. Neither was wrong, exactly, but neither was particularly helpful either. Jordan’s situation is one I see come up constantly: two types of hair loss that look vaguely similar in a bathroom mirror but that point toward different causes, different trajectories, and sometimes different treatments.
The distinction between diffuse thinning and Norwood-pattern recession matters more than most guys realize. Getting it wrong means you could spend a year on a treatment protocol aimed at the wrong problem.
The Classification System That Won’t Die
Pattern hair loss has been formally studied since James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences, where he observed that men castrated before puberty never developed the familiar temples-and-crown recession. That single observation cemented the role of androgens in male hair loss and shaped everything that followed.
O’Tar Norwood extended Hamilton’s framework in 1975 (Southern Medical Journal), expanding it from three stages to seven, with variant subtypes including the Type A variant where loss marches straight back from the front rather than hollowing out the temples and vertex independently. The combined Hamilton-Norwood scale has now survived over 70 years of attempted replacements, including the basic and specific (BASP) classification proposed in 2007. None of the alternatives have displaced it in everyday clinical practice, partly because it’s good enough, and partly because dermatologists are creatures of habit.
Diffuse thinning fits awkwardly into this framework. A guy with uniform density loss across his entire scalp doesn’t land neatly on the Norwood chart. His miniaturization isn’t concentrated at the hairline or crown. It’s everywhere, sometimes including the occipital region that Norwood-pattern loss typically spares. That’s the first diagnostic clue.
The distinction between these two presentations, diffuse thinning and patterned recession, is central to the standard diagnostic workflow for hair loss. For a deeper visual walkthrough with photographic staging examples, you can review this in-depth comparison, which lays out additional clinical context.
What’s Actually Happening at the Follicle
The biology underneath pattern hair loss is relatively well understood at this point. Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase, binds to androgen receptors in the dermal papilla of genetically susceptible follicles. Over successive growth cycles, the anagen phase shortens, the telogen phase stretches, and the dermal papilla itself physically shrinks. Thick terminal hairs become thin, short, unpigmented vellus hairs. Eventually they contribute almost nothing to visible coverage.
The genetics are polygenic. The androgen receptor gene on the X chromosome gets the most attention (hence the “look at your mother’s father” folk wisdom), but autosomal loci on the paternal side matter too. Family history is a rough guide, not a blueprint.
Diffuse thinning can share this androgen-driven mechanism, but it can also stem from entirely different causes: telogen effluvium triggered by illness, surgery, crash dieting, or severe stress; iron deficiency (ferritin below 30 ng/mL in women, or below 50 ng/mL when hair loss is the presenting concern); thyroid dysfunction; nutritional gaps. Sometimes it’s both. A guy with underlying androgenetic alopecia who goes through a stressful divorce may see diffuse shedding layered on top of early pattern loss. Teasing those apart requires more than a glance.
How Dermatologists Actually Sort This Out
The AAD’s clinical guidelines emphasize a structured evaluation: patient history, family history, physical scalp exam, trichoscopy, and selective lab work. The boring truth is that most of the diagnostic heavy lifting happens in the history and the dermoscope, not in blood draws.
Timeline matters enormously. Norwood-pattern loss is typically gradual, progressive, and measured in years. Diffuse thinning from telogen effluvium usually has a discrete onset, two to three months after a triggering event, and the patient can often pinpoint when shedding ramped up. “It started in March, right after I had COVID” is a very different story from “I think it’s been getting thinner for three years.”
Trichoscopy adds resolution the naked eye can’t match. In androgenetic alopecia, you see hair shaft diameter variability (caliber variability of 20% or more), yellow dots from empty follicular ostia, and density loss concentrated in the frontal and vertex zones with occipital preservation. In diffuse telogen effluvium, the miniaturization is less pronounced, and the density reduction is more uniform.
Lab work is selective, not shotgun. Ferritin, TSH, vitamin D, CBC when telogen effluvium is on the table. The AAD does not recommend routine androgen panels in men with classic pattern loss because the diagnosis is clinical.
Standardized photography (front, top, sides, back, consistent distance and lighting) is underrated. It turns subjective worry into objective data over months.
Treatment: What the Evidence Actually Supports
Here’s where the diffuse vs. patterned distinction has real consequences. If your thinning is primarily telogen effluvium from identifiable causes, the right move is to address the trigger, replete nutritional deficits, and wait. Starting finasteride won’t fix iron-deficiency shedding. Conversely, if trichoscopy reveals widespread miniaturization consistent with androgenetic alopecia happening in a diffuse pattern (which does occur, particularly in younger men), then the standard pharmacologic toolkit applies.
That toolkit, roughly ordered by evidence strength:
Oral finasteride 1 mg daily has the deepest evidence base. The five-year randomized trial published in JAAD (2002) showed sustained hair count improvements and favorable patient self-assessment versus placebo. Sexual side effects affect a small percentage in controlled trials and are generally reversible on discontinuation. My honest take: finasteride remains the single most effective thing most men can do, and the internet has made its side-effect profile sound far scarier than the trial data warrant.
Topical minoxidil 5% twice daily is FDA-approved, available over the counter, and works through mechanisms that aren’t fully mapped (potassium channel opening, vasodilation, direct follicle effects prolonging anagen). Visible response typically appears at three to six months. Foam and solution are clinically equivalent; foam causes less scalp irritation in some users.
Low-dose oral minoxidil (0.25 to 5 mg daily) gained serious traction after Vañó-Galván et al. published safety data on 1,404 patients in JAAD (2021). The side-effect profile at low doses proved more manageable than the drug’s cardiovascular history suggested, though periorbital edema and hypertrichosis still show up.
Dutasteride inhibits both type I and type II 5-alpha reductase isoforms, drops DHT more aggressively than finasteride, and has shown larger hair density improvements in head-to-head trials (Olsen et al., JAAD, 2006). It’s approved for benign prostatic hypertrophy, used off-label for hair.
PRP and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published several smaller randomized trials with positive but variable results (Gentile & Garcovich, Int J Mol Sci, 2020). Reasonable additions, not substitutes.
Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles from the donor zone to thinning areas. Best suited for stable loss patterns with adequate donor capacity.
What Treatment Actually Costs (No One Likes Talking About This)
Generic finasteride 1 mg: $10 to $25/month at US pharmacies with discount cards, sometimes $5 to $15 through telehealth platforms. Branded Propecia runs $70 to $90/month with no documented clinical advantage. That price delta is, frankly, absurd.
Generic topical minoxidil 5%: $10 to $30/month. Branded Rogaine roughly doubles that.
Low-dose oral minoxidil: often under $15/month in generic form. The cost driver is the prescribing visit ($50 to $150 via telehealth, or covered through a routine derm visit with insurance).
Hair transplantation in the US: $4 to $10 per graft for FUE, putting a typical 2,500 to 3,500 graft case at $10,000 to $35,000. In Turkey, similar graft counts run $2,000 to $5,000 total, reflecting labor cost differences rather than necessarily quality differences.
PRP: $500 to $1,500 per session, with most protocols calling for three to four sessions the first year plus maintenance. First-year PRP costs can exceed an entire year of combination medical therapy.
Insurance generally classifies pattern hair loss as cosmetic. HSAs and FSAs may cover prescribed medications and physician visits but typically exclude surgical procedures.
When to Stop Googling and See a Dermatologist
Self-management is reasonable in many cases. But some scenarios genuinely need in-person evaluation:
Sudden, diffuse shedding within the last six months (probable telogen effluvium requiring workup of the precipitating cause). Patchy loss with smooth, circumscribed bald spots (probable alopecia areata, a completely different condition). Any scalp pain, burning, redness, scaling, or visible scarring (possible scarring alopecia like lichen planopilaris or frontal fibrosing alopecia, where prompt diagnosis matters because destroyed follicles don’t come back; Kassira et al., JAAD, 2017). Hair loss in women with irregular periods, acne, or excess body hair (warrants endocrine evaluation). Rapid progression, more than one Norwood stage per year, in a young patient. And hair loss that hasn’t responded to documented use of standard therapy over 12 months.
The AAD’s position is straightforward: any progressive hair loss that concerns the patient is a legitimate reason for consultation. That’s a low bar, and it should be.
FAQs
How long does it take to see results from finasteride?
Shedding stabilization often becomes apparent in three to six months. Visible regrowth, when it happens, typically shows between six and twelve months. Full effect is assessed at one year.
Is the Norwood scale used for women?
No. Female pattern hair loss is classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
Is oral minoxidil better than topical?
Low-dose oral minoxidil produces comparable effects to topical with better adherence for many patients. The choice depends on side-effect tolerance and patient preference and should involve a prescribing clinician.
Should I get a hair transplant if I am in my 20s?
Experienced surgeons approach transplantation in patients in their 20s cautiously because long-term progression isn’t yet established. Medical therapy to stabilize native hair is usually prioritized first.
Can pattern hair loss be reversed?
Partially, in some patients, with early combination treatment (finasteride plus minoxidil) started before substantial follicular dropout. Late-stage loss with extensive miniaturization is generally not reversible with medical therapy alone.
Is hair loss covered by insurance?
Pattern hair loss treatment is generally classified as cosmetic and not covered. Some HSA and FSA accounts cover prescribed medications and physician visits.
How do I know if my thinning is diffuse or patterned?
The key differentiators are distribution (uniform vs. concentrated at temples/crown), timeline (acute onset vs. gradual progression), occipital involvement (spared in Norwood, sometimes affected in diffuse thinning), and trichoscopic findings. A dermatologist with a dermoscope can usually sort this out in a single visit.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
